Venetoclax Oral Tablet

DRUG7 trials

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCLL TransformationChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaLeukemia, Myeloid, AcuteMyelodysplastic Syndrome With Excess Blasts-2Myelodysplastic Syndromes

Phase 1

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

RecruitingNCT03850574

Aptose Biosciences Inc.Chronic Myelomonocytic Leukemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndrome With Excess Blasts-2 +2

Start: 2019-03-11End: 2027-04-30Target: 240Updated: 2025-08-26

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

CompletedNCT04330820

Technische Universität DresdenRefractory AML, Relapsed Adult AML

Start: 2020-04-06End: 2025-09-24Updated: 2026-09-02

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

RecruitingNCT05342584

Montefiore Medical CenterAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2022-05-25End: 2028-12-31Target: 99Updated: 2026-01-08

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

NCT06087419

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia

Start: 2023-10-30End: 2025-12-30Target: 42Updated: 2023-11-02

Phase 2

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruitingNCT04082897

Niguarda HospitalCLL Transformation

Start: 2019-10-04End: 2026-12-31Updated: 2024-05-28

VA vs DA for Newly Diagnosed Hig-risk AML

RecruitingNCT05939180

The First Affiliated Hospital of Soochow UniversityAcute Myeloid Leukemia

Start: 2024-04-01End: 2028-05-13Target: 116Updated: 2026-09-02

Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

Not yet recruitingNCT07738887

The Lymphoma Academic Research OrganisationChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2026-12-31End: 2032-06-30Target: 44Updated: 2026-07-31

Blood2025-02-079 citations

Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia

Cancer Research Communications2024-12-123 citations

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Blood2024-11-051 citations

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Blood2024-11-05

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.

2024-09-1021 citations

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood2023-11-0214 citations

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Blood2023-11-022 citations

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

HemaSphere2023-08-011 citations

PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX

HemaSphere2023-08-01

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML

HemaSphere2023-08-01

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Journal of Clinical Oncology2023-06-0111 citations

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Hematological Oncology2023-06-012 citations

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood2022-11-1510 citations

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Blood2022-11-15

P461: MYELOID KINOME INHIBITOR HM43239 OVERCOMES ACQUIRED RESISTANCE IN ACUTE MYELOID LEUKEMIA MODELS

HemaSphere2022-06-01

First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)

Blood2021-11-056 citations

Abstract 1257: HM43239, a novel FLT3 inhibitor, has the potential to inhibit mutations resistant to FLT3 inhibitors

Cancer Research2021-07-012 citations

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

Blood2020-11-042 citations

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Blood2019-11-136 citations

Venetoclax Oral Tablet

Sponsors

Conditions

Phase 1

Phase 2

Related Papers